

Safety Alert

March 2025

Semaglutide-Risks of Pulmonary Aspiration, intestinal obstruction & dysesthesia

EDA performs label update to include the following:

Special warnings and precautions for use

Aspiration in association with general anaesthesia or deep sedation

Cases of pulmonary aspiration have been reported in patients receiving GLP-1 receptor agonists undergoing general anaesthesia or deep sedation. Therefore, the increased risk of residual gastric content due to delayed gastric emptying (should be considered prior to performing procedures with general anaesthesia or deep sedation.

Undesirable effects:

Gastrointestinal Disorders:

Not known: Intestinal obstruction

Nervous System Disorders:

Common: dysesthesia

Background:

Therapeutic Indication

Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise

- As monotherapy when metformin is considered inappropriate due to intolerance or contraindications
- In addition to other medicinal products for the treatment of diabetes.

References:

EMA ([Click here](#))